Citations

Clear

4847 citation(s) found for "Tu, Eric".

Atlanto-occipital and atlanto-axial injections in the treatment of headache and neck pain
Busch, Eric H., Wilson, Peter

Mayo Clinic

Regional Anesthesia: The Journal of Neural Blockade in Obstetrics, Surgery, & Pain Control | October 11, 2025 | Volume: 14 | Issue: Suppl 2 | Pages: 45-45

10.1136/rapm-00115550-198914021-00045 Get It

Neurological Injuries Associated With Regional Anesthesia
Sorenson, Eric J., Sorenson, Eric J.

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 11, 2025 | Volume: 33 | Issue: 5 | Pages: 442-448

10.1136/rapm-00115550-200809000-00007 Get It

A peripheral nerve or spinal cord injury is a rare but significant complication of regional anesthesia. Evaluation of acute nerve injury includes a focused history and examination to localize the lesion. Confirmatory testing should include electromyography and appropriate imaging. In most cases magnetic resonance imaging (MRI) is preferred to computed tomography (CT) or ultrasound given the better resolution of the nerves and soft tissue. Most cases of peripheral nerve injury will improve and resolve without deficit. In mild cases reassurance and observation is all that is necessary. In more severe cases, if the deficit is progressive or complete, surgical exploration should be considered. If there is no recovery by 2 to 5 months then referral to a peripheral nerve surgeon should be considered. The prognosis for cauda equina or spinal cord lesions is more guarded. Recovery from these is commonly incomplete. Early diagnosis and intervention is the key to preventing catastrophic neurological outcomes.
Cardiovascular Outcomes in Patients With Cancer Undergoing Cardiac Implantable Electronic Device Implantation
Krishan, Satyam , Munir, Muhammad Bilal, Yang, Eric H., Torbey, Estelle , Cheng, Richard K. , Munir, Muhammad Bilal , Torbey, Estelle , Munir, Muhammad Bilal , Cheng, Richard , Agarwal, Siddharth, Ajijola, Olujimi A. , Yang, Eric H., Deswal, Anita M , Asad, Zain Ul Abideen

Mayo Clinic

Pacing and Clinical Electrophysiology | October 10, 2025 | Volume: 48 | Issue: 11 | Pages: 1309-1319

10.1111/pace.70061 | PMID 41071242 Get It

ABSTRACT Background Patients with cancer undergoing cardiac implantable electronic device (CIED) implantation face unique challenges. This study evaluates the outcomes and implications of CIED implantation in this population. Methods Using data from the National Readmission Database (NRD) from 2016 to 2019, we analyzed CIED implantations in patients aged ≥18 years, categorized by cancer status: no cancer, historical cancer, and active cancer. Multivariable logistic and linear regression models assessed associations with in‐hospital, 30‐day, and 90‐day outcomes, adjusting for various patient characteristics. Results A total of 748,957 CIED procedures were analyzed among which 13.3% were in patients with historical cancer and 3.8% with active cancer. Active cancer was linked to higher odds of pacemaker implantation but lower odds for ICD and CRT devices. Patients with active cancer experienced higher index hospitalization mortality (aOR 1.68; 1.50–1.89; p < 0.001), major adverse cardiovascular events (aOR 1.07; 1.02–1.14; p = 0.01), bleeding (aOR 1.36; 1.27–1.46; p < 0.01), and sepsis‐related (aOR 1.31; 1.19–1.44; p < 0.01) complications, with increased readmission rates at 30 (aOR 1.37; 1.30–1.44; p < 0.01) and 90 days (aOR 1.37; 1.31–1.44; p < 0.01) compared to those without cancer. Historical cancer was associated with better outcomes. Key predictors of adverse outcomes included chronic heart failure, kidney disease, cerebrovascular disease, and protein‐calorie malnutrition. Conclusions Patients with active cancer undergoing CIED implantation have an increased risk of in‐hospital complications and readmissions as compared to those without cancer.
Incidence of chronic medical conditions among survivors of adolescent and young adult cancer compared to a population without cancer
Keegan, Theresa H.M. , Abrahão, Renata , Chubak, Jessica , Sauder, Candice A. M. , Ruddy, Kathryn J. , Li, Qian , Haupt, Eric C. , Laurent, Cecile A. , Casperson, Mallory, Chao, Chun , Smitherman, Andrew B. , Nichols, Hazel B. , Chao, Chun , Smitherman, Andrew B , Nichols, Hazel B , Hahn, Erin E , Chubak, Jessica , Quesenberry, Charles P. , Li, Qian , Brunson, Ann , Kirchhoff, Anne C. , Kushi, Lawrence H.

Mayo Clinic

Cancer | October 10, 2025 | Volume: 131 | Issue: 20 | Pages: No page available

10.1002/cncr.70125 | PMID 41070762 Get It

Abstract Background Few studies have assessed the burden of chronic medical conditions in adolescent and young adult (AYA) cancer survivors. This study estimated the risk of these conditions among AYA survivors compared to a matched cohort without cancer. Methods This retrospective cohort study included 2‐year survivors ( n = 14,917) of 11 common AYA (15–39 years) cancers diagnosed at the integrated health care organizations of Kaiser Permanente (KP) Southern and Northern California during 2006–2020. A comparison cohort ( n = 149,164) without cancer (matched 10:1 by age, sex, calendar year, and KP site) was included. Cumulative incidence (CMI) accounting for death as a competing risk was calculated. Poisson regression estimated the incidence rate ratio (IRR) of each condition in cancer survivors versus the matched cohort, adjusting for age, sex, and race/ethnicity. Results The 5‐year CMI was highest for thyroid (17.4%), respiratory (6.6%), cardiovascular (5.0%), and liver (4.8%) diseases. At 10 years, the CMI of any condition was 39% in survivors versus 26% in the matched cohort. Survivors had a 2‐fold increased risk of being diagnosed with any medical condition (IRR, 2.0; 95% confidence interval [CI], 1.9–2.0) as well as two or more conditions (IRR, 2.3; 95% CI, 2.2–2.5). Risk was highest among survivors of hematologic cancers and those diagnosed with distant stage disease. Elevated risks were observed within all sociodemographic groups of this insured population. Conclusion AYAs with cancer had a higher risk of chronic medical conditions compared to those without cancer. Long‐term surveillance, risk mitigation through lifestyle modifications and effective disease management are crucial to reduce premature mortality.
Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women
Keil, Alexander P. , Taylor, Jack A. , Yadav, Siddhartha , Culver, Hoda Anton, Auer, Paul L. , Bodelón, Clara , Haiman, Christopher A., Lindströem, Sara, Martinez, Maria Elena, Nathanson, Katherine L. , Patel, Alpa V. , Penney, Kathryn L., Ruddy, Kathryn J. , Teras, Lauren R., Vachon, Celine M. , Weitzel, Jeffrey N. , Yao, Song, Weitzel, Jeffrey N , Yadav, Siddhartha , Taylor, Jack A , Nathanson, Katherine L , O’Brien, Katie M. , Weinberg, Clarice R. , Polley, Eric C. , Boddicker, Nicholas , Hu, Chunling , Ambrosone, Christine B. , Brantley, Kristen D. , Burnside, Elizabeth S. , Chen, Fei , Domchek, Susan M. , Eliassen, A. Heather , Hodge, James M. , Kraft, Peter , Lacey, James V. , Neuhausen, Susan L. , Olson, Janet E. , Palmer, Julie R. , Penney, Kathryn , Scott, Christopher G. , Teras, Lauren R. , Trentham‐Dietz, Amy , Vachon, Celine M. , Yao, Song , Zirpoli, Gary , Couch, Fergus J. , Sandler, Dale P.

Mayo Clinic

JAMA Oncology | October 9, 2025 | Volume: 11 | Issue: 12 | Pages: 1458

10.1001/jamaoncol.2025.3875 | PMID 41066089 Get It

Importance Inherited pathogenic variants (PVs) in known predisposition genes can greatly increase breast cancer risk, but the combined impact of PV status, family history, and other factors on breast cancer risk in the general US population has not been well described. Objective To evaluate population-based breast cancer risk estimates for those with established PVs overall and stratified by first-degree family history of breast cancer and other factors. Design, Setting, and Participants This study used pooled data from 13 US-based breast cancer case-control studies participating in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. Enrollment for individual studies occurred between 1976 and 2013, and results are based on data released March 2023, with analyses conducted from June 2022 to July 2025. Exposures PVs, breast cancer family history, self-reported race and ethnicity, and established risk factors. Main Outcomes and Measures Breast cancer rate ratios for PVs in 7 genes were estimated from the CARRIERS consortium. PV status and incidence and mortality statistics were combined using the Individualized Coherent Absolute Risk Estimation (iCARE) model to estimate conditional cumulative breast cancer risks and 95% CIs, stratified by family history and standardized to the US population. Models that incorporated population-based data and published estimates for established epidemiologic risk factors were also evaluated. Results A total of 67 692 women were studied, including 33 841 who were diagnosed with breast cancer. PVs in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2 were strongly associated with breast cancer risk, with BRCA1 and PALB2 PVs showing evidence of heterogeneity by family history. In models considering PVs, family history, and established risk factors, the estimated cumulative risks of breast cancer by age 50 years ranged from 2.4% (95% CI, 2.4-2.4) in women with no PVs and no family history to 35.5% (95% CI, 21.6-55.1) in PALB2 PV carriers with a family history. Among women who have not been diagnosed with breast cancer by age 50 years, the cumulative risk of breast cancer by age 80 years ranged from 11.1% (95% CI, 11.0-11.2) in noncarriers with no family history to 70.5% (95% CI, 52.8-83.5) for PALB2 carriers with a family history. PV-specific cumulative risk estimates varied across subgroups defined by race and ethnicity and potentially modifiable epidemiologic risk factors. Conclusions and Relevance In this study, population-based estimates of cumulative breast cancer risk for established PVs, as informed by the CARRIERS case-control sample, varied by family history and potentially modifiable risk factors. These estimates provide guidance for identifying individuals who will most benefit from enhanced screening and prevention strategies.
Voice and Choice: Voice Equivalence and Representational Choice in Virtual Health Assistants for Colorectal Cancer Screening Among Black American Adults
Maxim, Andrew , Cooks, Eric , Krieger, Janice L. , Lok, Benjamin

Mayo Clinic

Proceedings of the 25th ACM International Conference on Intelligent Virtual Agents | October 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.1145/3717511.3747065 | PMID 42898760 Get It

From GWAS to Translational Insights: Comprehensive Genetic Analysis of Nephrotic Syndrome from Multiple Populations
Seagle, Hannah M. , Akerele, Alexis T., Ahn, Kwangmi , Torstenson, Eric S. , Zhang, Yanfei , Jarvik, Gail P., Dikiltas, Ozan, Lee, Ming Ta Michael , Fargo, David C. , Rowley, Robb , Kiryluk, Krzysztof, Hellwege, Jacklyn N. , Breeyear, Joseph H. , Khankari, Nikhil K. , Burkholder, Adam , House, John S. , Kullo, Iftikhar J. , Kiryluk, Krzysztof , Woychik, Richard P. , Motsinger‐Reif, Alison A. , Suszták, Katalin , Edwards, Todd L.

Mayo Clinic

No container title available | October 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7482306/v1 Get It

Abstract Nephrotic syndrome is a rare, heterogeneous kidney disorder characterized by proteinuria, hypoalbuminemia, and edema. To elucidate its genetic architecture, we conducted a large-scale, electronic health record (EHR)-linked, multi-ancestry genome-wide association study comprising 5,214 cases and 1,601,060 controls. We identified 37 distinct loci associated with disease risk, including novel associations at JAML and STPG2 , and confirmed prior signals at PLA2R1 , HMCN1 , and APOL1 . Fine-mapping of the major histocompatibility complex (MHC) revealed the strongest association at DRB103:01:01G in individuals of European ancestry (OR = 2.01, P = 1.4×10⁻²⁰), alongside nominal ancestry-specific associations in African ( DOA01:01:05 ) and Latino ( DPB1*14:01:01G ) populations. Transcriptome-wide association analysis (TWAS) identified 484 significant gene-tissue associations, including C4A in kidney cortex. Expression quantitative trait locus (eQTL) mapping revealed numerous cis-eQTLs in glomerular and tubular renal tissues, largely within the MHC region. We observed significant genetic correlation between adult and pediatric nephrotic syndrome (Rg = 0.63, P = 3.5x10 -11 ), suggesting shared genetic etiology. Pathway analyses implicated estrogen receptor signaling and histone modification. Mendelian randomization implicated APOM expression and apomorphine exposure with increased disease risk (OR = 4.93, P = 1.8x10 -19 ). These results expand the understanding of nephrotic syndrome pathogenesis and highlight ancestry-informed targets for therapeutic development.
Complications From Cochlear Implantation and Management of Noncholesteatoma Chronic Otitis Media With Perforation: A Systematic Review and Meta-analysis
Rendon, Eric Delgado , Wilson, Prishae, Kabat, Natalia M., Rosasco, Robyn , Raymond, Mallory , Wilson, Penny , Delgado Rendon, Eric , Wilson, Prishae , Wilson, Prishae, Wang, Zhen , Raymond, Mallory J

Mayo Clinic

Otology & Neurotology | October 8, 2025 | Volume: 47 | Issue: 1 | Pages: 132-138

10.1097/mao.0000000000004651 | PMID 41058027 Get It

Objective: To compare postoperative complications between staged versus unstaged tympanoplasty and subtotal petrosectomy (STP) in adults undergoing cochlear implants with noncholesteatoma chronic otitis media (NCCOM) and tympanic membrane perforation. Databases reviewed: PubMed/MEDLINE, Cochrane CENTRAL, Embase, CINAHL, Web of Science, WHO Global Index Medicus, ClinicalTrials.gov, and WHO ICTRP. Materials and methods: A systematic search of databases was conducted by a research librarian from inception through November 18, 2024. Eligible studies for inclusion must have reported on adult cochlear implant recipients undergoing surgical management of NCCOM with perforation. Using a random effects model, complication rates were pooled and compared between staged and unstaged surgeries using relative risk (RR) with 95% CI. Results: Of 1265 studies identified, 19 met inclusion criteria (n = 84). Fifty three (63.1%) patients underwent unstaged surgery. Amongst all patients, STP was performed more than tympanoplasty (72.6%, 61/84 vs 27.4%, 23/84), and the overall complication rate was 11.9% (10/84). There was no significant difference in complication rates between combined staged and unstaged surgeries [RR: 1.13 (95% CI, 0.18-7.04)] as well staged and unstaged tympanoplasty [RR: 0.34 (95% CI, 0.11-0.1.01)]. However, complication rates were lower for staged than unstaged STP [RR: 0 (95% CI, 0.0-0.07)]. Conclusion: Staged and unstaged surgery for NCCOM and cochlear implant may result in comparable complication rates, however the wide CIs for RR statistics in comparisons between combined staged and unstaged procedures as well as staged and unstaged tympanoplasty indicate a need for similar studies of larger populations.
Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications
Ghusn, Wissam , Sridharan, Mira, Fromer, Rachel, Ozdemir, Muhammet , Haff, Madeleine , Haff, Madeleine G , Ghusn, Wissam , Sridharan, Mira , Ozdemir, Muhammet, Vargas, Eric J.

Mayo Clinic

Biomedicines | October 7, 2025 | Volume: 13 | Issue: 10 | Pages: 2437

10.3390/biomedicines13102437 | PMID 41153720 Get It

Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly emerging as the leading cause of chronic liver disease, closely tied to rising global obesity rates. Endoscopic bariatric therapies (EBTs), including endoscopic sleeve gastroplasty (ESG), intragastric balloons (IGB), duodenal-jejunal bypass liners (DJBL), and duodenal mucosal resurfacing (DMR), offer minimally invasive interventions that target metabolic dysfunction and weight loss. This review synthesizes current evidence on the mechanisms and hepatic outcomes of EBTs in MASLD, highlighting improvements in hepatic steatosis, liver stiffness, and fibrosis biomarkers across multiple modalities. ESG is consistently associated with reductions in hepatic steatosis and fibrosis scores across multiple studies. IGB therapy improves liver stiffness and reduces hepatic fat as assessed by imaging modalities such as MRI- Proton Density Fat Fraction and ultrasound. DJBL lowers liver enzymes and improves non-invasive markers of steatohepatitis like the Fibroscan-AST score, although its effect on fibrosis appears limited. DMR demonstrates reductions in liver fat, particularly in patients with type 2 diabetes, but evidence for histological improvement in MASLD remains inconsistent. Despite their promise, most EBT studies remain limited by small sample sizes and short follow-up. Further randomized trials are needed to validate long-term efficacy and position EBTs alongside or as alternatives to surgical interventions for MASLD.
P11.14.A STEREOTACTIC RADIOSURGERY FOR OVARIAN CANCER BRAIN METASTASES: AN INTERNATIONAL RADIOSURGERY RESEARCH FOUNDATION RETROSPECTIVE STUDY
Mathieu, D, Billau, Mathilde Djeneba, Adam, Elizabeth , Iorio‐Morin, Christian , Liscak, R, Niranjan, A, Wei, Zheng , Lunsford, L. Dade , José, São, Scanlon, Samantha, Silverman, Joshua B., Mullen, Russell , Bernstein, Kenneth , Samanci, Yavuz, Düzkalır, Ali Haluk , Phuong, Christina , Sheehan, Jason , Pikis, Styllianos, Kosyakovsky, Jacob, Prasad, Rajendra , Cifarelli, Daniel T. , Icaza, Denisse Arteaga, Wegner, Rodney E. , Shepard, M J, Bowden, Greg , Wandrey, Narine , Rusthoven, Chad G. , Hintz, Eric , Schulder, Michael , Goenka, Anuj , Peterson, Jeffrey J., Mathieu, David , Hamel, Andréanne, Liscak, R, May, Jaromír , Niranjan, A, Wei, Z, Luy, Diego D. , Silverman, J, Kondziolka, Douglas , Peker, Selçuk , Samancı, Yavuz , Braunstein, Steve , Prasad, R N, Palmer, Joshua D. , Bailey, D, Zacharia, Brad E. , Cifarelli, Christopher P.

Mayo Clinic

Neuro-Oncology | October 3, 2025 | Volume: 27 | Issue: Supplement_3 | Pages: iii106-iii106

10.1093/neuonc/noaf193.353 Get It

Abstract BACKGROUND Ovarian cancer rarely metastasises to the brain, thus studies reporting the outcomes of affected patients are lacking. Stereotactic radiosurgery (SRS) is now the mainstay of management for patients with brain metastases (BM) from most primary sites, but little evidence of its efficacy in ovarian cancer is available. The current study was undertaken to provide guidance for SRS management using pooled data from multiple institutions. MATERIAL AND METHODS Centers participating in the IRRF (International Radiosurgery Research Foundation) were asked to provide outcome data for patients who had SRS for ovarian cancer brain metastases between 2020 and 2024 and at least one clinical and imaging follow-up after the procedure. Primary endpoints included survival from SRS, local tumor response according to RANO-BM criteria and occurrence of adverse radiation effects (ARE). Cox regression analyses were performed to identify variables impact each endpoint. RESULTS 128 patients had SRS for a total of 532 BM treated. Epithelial histology was the most common (91%). Median age at SRS was 62 years (IQR 56-70). Median KPS was 80% (IQR 80-90%) and 71.9% of patients had neurological symptoms at presentation. Other active systemic metastases were present in 41.4%. The median number of treated BM was 2 (IQR1-3) and the median cumulative treatment volume was 6 cc (IQR 2-12.9). The median margin dose was 18 Gy (IQR 16-20). At last follow-up, 19.5% of patients were still alive. The median overall survival (OS) after SRS was 27 months, and 6-, 12- and 24-month OS was 83.8%, 74.2% and 52.2%, respectively. Multivariate analyses revealed that increasing age at SRS (HR 1.02, p=0.05), active systemic metastases (HR 2, p=0.005) and increasing number of brain metastases (HR 1.05, p=0.04) were associated with worse survival, while repeating SRS (HR 0.4, p=0.002) led to improved survival. Local failure occurred in 12.8% of treated BM. Actuarial progression-free survival (PFS) at 6, 12 and 24 months was 92.3%, 86.6% and 70.3%, respectively. Only prior WBRT (HR 4.36, p=0.03) led to worse local control on multivariate analyses. New remote BM appeared in 49.5% of patients and 14.5% suffered from leptomeningeal dissemination. ARE were seen in 12.1% of BM but were symptomatic in only 3.2%. On multivariate analyses, prior SRS (HR 3.13, p=0.002) was associated with increased risk of ARE. CONCLUSION Ovarian cancer brain metastases can be safely and effectively managed with SRS as the primary treatment modality in most patients.